cells effectively eliminates CD7+ AML cell lines, primary CD7+ AML, and colony-forming cells but spares myeloid and erythroid progenitor cells and their progeny. In a xenograft model, CD7 CAR T?cells protect mice against systemic leukemia, prolonging survival. Our results support the feasibility ...
⭐4.CAR-T（北京博仁医院CD7-CAR-T，Ⅱ期）—Ⅰ期数据显示完全缓解的有效性，可控的安全性 （Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial）⭐5. WU-CART-007（Wugen 的CD7-CAR-T，Ⅱ期）—公开的IND效果好，预计主要...
T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially...
⭐4.CAR-T(北京博仁医院CD7-CAR-T,Ⅱ期)—Ⅰ期数据显示完全缓解的有效性,可控的安全性 (Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的I...
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) 5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
参考文献:Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management,doi:10.1158/1078-0432.CCR-20-1271; 识别微信二维码,添加生物制品圈小编,符合条件者即可加入生物制品微信群!
近日，一项聚焦自体CD7 CAR-T治疗儿童R/R T-ALL的研究“Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial”发表于Molecular Therapy（IF:12.4），初步探索和揭示无T细胞分选的自体CD7 CAR-T细胞的制备、以及其治疗r/r...
1987, 325(6101): 545-549.2. Mataraza J M, et al. CD7 gene expression reveals a subset of CD3- CD4- CD8- CD45RO+ lymphocytes that appear during HIV infection[J]. Clin Immunol Immunopathol. 1993, 66(2): 223-230.3. Debolts S L, et al. γδ TCR+CD7+ Natural Killer T Cells ...
他们新的简化方法选择了一种有利的T细胞类型,并在实验室中显示出对抗复发的T细胞急性淋巴细胞白血病(T-ALL)的前景。相关研究结果于2022年8月1日在线发表在Blood期刊上,论文标题为“Engineering Naturally Occurring CD7 Negative T Cells for the Immunotherapy of Hematological Malignancies”。 急性淋巴细胞白血病(ALL)...